Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 68Terminated 13Active not recruiting 9Unknown 8Withdrawn 5Recruiting 5Suspended 1

Sponsor Class

OTHER 96INDUSTRY 22NIH 5OTHER_GOV 3FED 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Neoplasms 14Multiple Myeloma 11Lymphoma 11Breast Neoplasms 10Melanoma 7Neoplasm Metastasis 6Colorectal Neoplasms 6Sarcoma 5Ovarian Neoplasms 5Lung Neoplasms 5Leukemia 5Colonic Neoplasms 5Carcinoma, Hepatocellular 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroblastoma 3Neoplasms, Plasma Cell 3Mesothelioma, Malignant 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3

Interventions

tazemetostat 1Vancomycin 1Pharmacogenomic Testing 1MK 2206 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × NIH × Carcinoma, Hepatocellular × Clear all
NCT03748927 2020-03-26

Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma

National Institutes of Health Clinical Center (CC)

Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04025567 2020-03-16

Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT03217253 2020-02-07

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT02599909 2018-09-20

Gut Microbiota in People With Hepatocellular Carcinoma (HCC)

National Institutes of Health Clinical Center (CC)

Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡